Ovid Therapeutics

Treatments for rare brain disorders

Also Clin3 Lennox-Gastaut syndrome; OV888 (partner: Graviton) Clin1 brainstem malformations, rare CNS conditions; OV329 Clin1 epilepsies, RD/Clin0 seizures; OV350 RD/Clin0 epilepsies, neuropathologies; undisclosed programs RD undisclosed

Ovid Therapeutics is creating impactful medicines for patients with neurological diseases. Today, nearly 50 million people live with epilepsies and the current treatment options available are ineffective. Ovid’s strategy is to create therapies that ameliorate neuronal hyperexcitability that arise with conditions like seizures and epilepsies. Their pipeline consists of small molecule programs that pursue unique targets implicated in neuronal regulation. While other companies focus on novel modalities, Ovid is taking advantage of the versatility of small molecules for manufacturing, chemistry and dosing. Ovid’s pipeline includes diverse indications in preclinical or clinical stages.